Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension

Aim. To study Actovegin efficacy in oxidative stress (OS) correction at diabetic polyneuropathy (DPN) in patients with diabetes mellitus type 2 (DM2)and arterial hypertension (AH).Materials and Methods. 51 patients (24 women and 27 men) aged 53.4?0.7 with the average duration of DM2 5.6?0.2 years,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ivan Petrovich Gorshkov, Vladimir Ivanovich Zoloedov, Anna Petrovna Volynkina
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	diabetic polyneuropathy lipid peroxidation actovegin oxidative stress diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/69d066b79e9944b6b870f0143f223c9f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:69d066b79e9944b6b870f0143f223c9f
record_format	dspace
spelling	oai:doaj.org-article:69d066b79e9944b6b870f0143f223c9f2021-11-14T09:00:15ZClinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension2072-03512072-037810.14341/2072-0351-5680https://doaj.org/article/69d066b79e9944b6b870f0143f223c9f2010-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5680https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To study Actovegin efficacy in oxidative stress (OS) correction at diabetic polyneuropathy (DPN) in patients with diabetes mellitus type 2 (DM2)and arterial hypertension (AH).Materials and Methods. 51 patients (24 women and 27 men) aged 53.4?0.7 with the average duration of DM2 5.6?0.2 years, DPN - 4.9?0.2years and AH - 6.0?0.2 years were examined. Daily albuminuria, glomerular filtration rate (GRF) were evaluated, standard methods for diagnosisof DPN were used. 26 patients took Actovegin therapy during 6-8 weeks, the rest 25 patients were in the control group. Parameters of the OS werestudied. Results. The increase of total oxidative capacity, the decrease of total antioxidant capacity and the rise of levels of antibodies to oxidated LDL wererevealed in patients with DM2, DPN and AH. Antioxidant and anti-hypoxic effects of 400 mg/day of Actovegin were established in this group of patients.Conclusions. Actovegin impacts oxidative stress parameters and improves the clinical manifestation of diabetic polyneuropathy.Ivan Petrovich GorshkovVladimir Ivanovich ZoloedovAnna Petrovna VolynkinaEndocrinology Research Centrearticlediabetic polyneuropathylipid peroxidationactoveginoxidative stressdiabetes mellitusNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 2, Pp 84-89 (2010)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetic polyneuropathy lipid peroxidation actovegin oxidative stress diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetic polyneuropathy lipid peroxidation actovegin oxidative stress diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627 Ivan Petrovich Gorshkov Vladimir Ivanovich Zoloedov Anna Petrovna Volynkina Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
description	Aim. To study Actovegin efficacy in oxidative stress (OS) correction at diabetic polyneuropathy (DPN) in patients with diabetes mellitus type 2 (DM2)and arterial hypertension (AH).Materials and Methods. 51 patients (24 women and 27 men) aged 53.4?0.7 with the average duration of DM2 5.6?0.2 years, DPN - 4.9?0.2years and AH - 6.0?0.2 years were examined. Daily albuminuria, glomerular filtration rate (GRF) were evaluated, standard methods for diagnosisof DPN were used. 26 patients took Actovegin therapy during 6-8 weeks, the rest 25 patients were in the control group. Parameters of the OS werestudied. Results. The increase of total oxidative capacity, the decrease of total antioxidant capacity and the rise of levels of antibodies to oxidated LDL wererevealed in patients with DM2, DPN and AH. Antioxidant and anti-hypoxic effects of 400 mg/day of Actovegin were established in this group of patients.Conclusions. Actovegin impacts oxidative stress parameters and improves the clinical manifestation of diabetic polyneuropathy.
format	article
author	Ivan Petrovich Gorshkov Vladimir Ivanovich Zoloedov Anna Petrovna Volynkina
author_facet	Ivan Petrovich Gorshkov Vladimir Ivanovich Zoloedov Anna Petrovna Volynkina
author_sort	Ivan Petrovich Gorshkov
title	Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_short	Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_full	Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_fullStr	Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_full_unstemmed	Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_sort	clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
publisher	Endocrinology Research Centre
publishDate	2010
url	https://doaj.org/article/69d066b79e9944b6b870f0143f223c9f
work_keys_str_mv	AT ivanpetrovichgorshkov clinicalefficacyofoxidativestresscorrectionbyactoveginindiabeticpolyneuropathyattype2diabeticpatientswitharterialhypertension AT vladimirivanovichzoloedov clinicalefficacyofoxidativestresscorrectionbyactoveginindiabeticpolyneuropathyattype2diabeticpatientswitharterialhypertension AT annapetrovnavolynkina clinicalefficacyofoxidativestresscorrectionbyactoveginindiabeticpolyneuropathyattype2diabeticpatientswitharterialhypertension
_version_	1718429657483706368

Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension

Ejemplares similares